EFBO schreef op 29 oktober 2019 13:05:
Feiten
H2 19
Start phase II trial in acute kidney injury
Q2 20
Pre-eclampsia phase I/II trial safety component read-out
H2 20
Completion of leniolisib phase II/III trial
Q4 20
IND filing in Pompe disease
Q4 20/Q1 21
Full read-out on phase I/II trial in pre-eclampsia
Q1 21
Start clinical studies of new delivery methodsH1 21
Start phase I/II trial in Pompe disease
Mid-2021
Read-out on acute kidney injury phase II trial
2021
Read-out on investigator-initiated study in delayed graft function
H2 21 or H1 22
Launch of leniolisib subject to market approval
H1 22
Start phase I/II trial in Fabry disease